The reliability and validity of the revised Green et al. paranoid thoughts scale in individuals at clinical high-risk for psychosis.
clinical high risk
construct validity
paranoia
psychometric
psychosis
Journal
Acta psychiatrica Scandinavica
ISSN: 1600-0447
Titre abrégé: Acta Psychiatr Scand
Pays: United States
ID NLM: 0370364
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
27
01
2023
received:
29
09
2022
accepted:
21
02
2023
medline:
17
5
2023
pubmed:
12
3
2023
entrez:
11
3
2023
Statut:
ppublish
Résumé
Paranoia is a common and impairing psychosis symptom, which exists along a severity continuum that extends into the general population. Individuals at clinical high-risk for psychosis (CHR) frequently experience paranoia and this may elevate their risk for developing full psychosis. Nonetheless, limited work has examined the efficient measurement of paranoia in CHR individuals. The present study aimed to validate an often-used self-report measure, the revised green paranoid thoughts scale (RGPTS), in this critical population. Participants were CHR individuals (n = 103), mixed clinical controls (n = 80), and healthy controls (n = 71) who completed self-report and interview measures. Confirmatory factor analysis (CFA), psychometric indices, group differences, and relations to external measures were used to evaluate the reliability and validity of the RGPTS. CFA replicated a two-factor structure for the RGPTS and the associated reference and persecution scales were reliable. CHR individuals scored significantly higher on both reference and persecution, relative to both healthy (ds = 1.03, 0.86) and clinical controls (ds = 0.64, 0.73). In CHR participants, correlations between reference and persecution and external measures were smaller than expected, though showed evidence of discriminant validity (e.g., interviewer-rated paranoia, r = 0.24). When examined in the full sample, correlation magnitude was larger and follow-up analyses indicated that reference related most specifically to paranoia (β = 0.32), whereas persecution uniquely related to poor social functioning (β = -0.29). These results demonstrate the reliability and validity of the RGPTS, though its scales related more weakly to severity in CHR individuals. The RGPTS may be useful in future work aiming to develop symptom-specific models of emerging paranoia in CHR individuals.
Identifiants
pubmed: 36905387
doi: 10.1111/acps.13545
pmc: PMC10463775
mid: NIHMS1907842
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
623-633Subventions
Organisme : NIMH NIH HHS
ID : R01MH120088
Pays : United States
Organisme : NIMH NIH HHS
ID : R33 MH103231
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH112545
Pays : United States
Organisme : NIMH NIH HHS
ID : R01MH110374
Pays : United States
Organisme : NIMH NIH HHS
ID : R01MH103231
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH110374
Pays : United States
Organisme : NIMH NIH HHS
ID : R01MH120091
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH120091
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH120088
Pays : United States
Organisme : NIMH NIH HHS
ID : R01MH112545
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH103231
Pays : United States
Informations de copyright
© 2023 The Authors. Acta Psychiatrica Scandinavica published by John Wiley & Sons Ltd.
Références
Br J Psychiatry. 2005 May;186:427-35
pubmed: 15863749
Behav Ther. 2019 Jul;50(4):718-731
pubmed: 31208682
Psychol Med. 2021 Jan;51(2):244-253
pubmed: 31744588
Psychol Med. 2008 Jan;38(1):101-11
pubmed: 17903336
Early Interv Psychiatry. 2021 Jun;15(3):505-512
pubmed: 32337849
Compr Psychiatry. 2008 May-Jun;49(3):288-96
pubmed: 18396189
Biol Psychiatry Cogn Neurosci Neuroimaging. 2022 Nov;7(11):1149-1157
pubmed: 35430406
Schizophr Bull. 2020 Dec 1;46(6):1346-1352
pubmed: 32648913
Biol Psychiatry. 2011 Mar 1;69(5):424-31
pubmed: 21168124
Br J Clin Psychol. 2019 Mar;58(1):19-34
pubmed: 30028025
Schizophr Res. 2017 Dec;190:90-95
pubmed: 28372906
J Psychiatr Res. 2017 May;88:89-96
pubmed: 28103519
Brain. 2017 Sep 1;140(9):2475-2489
pubmed: 29050393
Schizophr Res. 2011 Jun;129(1):42-6
pubmed: 21511440
Schizophr Res. 2005 Nov 1;79(1):117-25
pubmed: 16276559
Schizophr Bull. 2019 Jun 18;45(4):763-772
pubmed: 30351423
Cogn Neuropsychiatry. 2013;18(6):531-48
pubmed: 23445398
Psychiatry Res. 2016 Apr 30;238:25-32
pubmed: 27086207
Behav Res Ther. 2007 Mar;45(3):523-37
pubmed: 16782048
Schizophr Bull. 2017 Sep 1;43(5):949-955
pubmed: 28911048
Psychol Assess. 2019 Feb;31(2):139-158
pubmed: 30234319
Clin Psychol Rev. 2001 Nov;21(8):1143-92
pubmed: 11702511
J Psychiatr Brain Sci. 2021;6(3):
pubmed: 34307899
Am J Psychiatry. 2016 Oct 1;173(10):980-988
pubmed: 27363508
Schizophr Res. 2021 Jan;227:72-77
pubmed: 32943313
Schizophr Res Cogn. 2016 Mar;3:33-38
pubmed: 27990352
Psychiatry Res. 2005 Nov 15;137(1-2):87-92
pubmed: 16226316
Dev Psychopathol. 2013 Nov;25(4 Pt 2):1585-600
pubmed: 24342857
Am J Psychiatry. 2014 Mar;171(3):332-9
pubmed: 24220644
Psychiatry Res. 2019 Dec;282:112492
pubmed: 31387769